Linyi Peng

Dr. Linyi Peng

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
LWLiwen Wang
Liwen Wang
PZPanpan Zhang
Panpan Zhang
MWMu Wang
Mu Wang
RFRuie Feng
Ruie Feng
YLYamin Lai
Yamin Lai
WZWen Zhang
Wen Zhang
The aim of this study was to assess the outcomes of remission induction in patients with IgG4-related disease (IgG4-RD) in our cohort, and to investigate the characteristics, prognosis, and risk factors in the patients failed of remission induction. We prospectively enrolled 215 newly diagnosed patients with IgG4-RD, who were initially treated with glucocorticoid (GC) alone or in combination with immunosuppressive agents (IM), and had at least 6 months of follow up. The therapeutic goals of remission induction were defined as fulfilling each of the following after the 6-month remission induction stage: (1) ≥ 50% decline in the IgG4-RD responder index (RI); (2) GC tapered to maintenance dose; and (3) no relapse during GC tapering. The patients not achieving the therapeutic goals were considered to have failed of remission induction. There were 26 patients in our cohort who failed of remission induction, including 16 (20.8%) on GC monotherapy, and 10 (7.2%) on combination therapy comprising GC and IM. The lacrimal gland and lung were most common sites of remission induction failure. Among the patients who relapsed during remission induction stage, 52.9% had secondary relapse during follow-up. Eosinophilia, higher baseline RI, more than five organs involved and dacryoadenitis were risk factors for remission induction failure with GC monotherapy, and the incidence of remission induction failure was 71.4% in the patients with more than three risk factors. After 6-month treatment, the patients who failed of remission induction had significantly higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and IgG4. In our cohort, 20.8% of patients failed of remission induction with GC monotherapy, while 7.2% of patients failed of remission induction with combination therapy comprising GC and IM.

12 January 2024 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LPLinyi Peng
Linyi Peng
YNYuxue Nie
Yuxue Nie
JZJiaxin Zhou
Jiaxin Zhou
LWLijun Wu
Lijun Wu
XCXiaomei Chen
Xiaomei Chen
WZWen Zhang
Wen Zhang
Objectives IgG4-related disease (IgG4-RD) is an immune-mediated, fibroinflammatory disease. Induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy for maintenance treatment a challenge. The WInS IgG4-RD (withdraw immunosuppressants (IMs) and steroid in stable IgG4-RD) trial tested whether discontinuation of GC and IM was feasible in stable IgG4-RD. Methods The WInS IgG4-RD trial was a multicentre, open-label, randomised controlled trial. Patients with IgG4-RD receiving GC+IM as maintenance treatment with clinically quiescent disease for at least 12 months were randomised (1:1:1) into three groups: group 1: withdraw GC+IM; group 2: withdraw GC but maintain IM; group 3: maintain GC+IM. The primary outcome was the relapse rate of disease within 18 months. The secondary outcomes included the changes of IgG4-RD Responder Index (RI), Physician’s Global Assessment (PGA), serum IgG4 and IgG, as well as adverse events. Results One hundred and forty-six patients were randomised, with 48 patients in group 1, 49 patients in group 2 and group 3, respectively. Within the 18-month follow-up period, disease relapse occurred in 25 out of 48 (52.1%) patients in group 1 vs 7 out of 49 (14.2%) in group 2 and 6 out of 49 (12.2%) in group 3 (p<0.001). The changes in RI and PGA were significantly higher in group 1 than in group 2 (p<0.001) or group 3 (p<0.001). Conclusions The maintenance of IMs, with or without low-dose GC, was found to be superior to withdraw GC+IM in preventing relapse for long-time stable IgG4-RD. Trial registration number NCT04124861.

1 January 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
FTFei Teng
Fei Teng
HLHui Lu
Hui Lu
KZKe Zheng
Ke Zheng
GCGang Chen
Gang Chen
YWYubing Wen
Yubing Wen
XLXuemei Li
Xuemei Li
Background . IgG4‐related disease is a new disease entity, but little attention was drawn to urinary system involvement besides nephritis or nephropathy. Here, we described clinical, radiological, and pathological manifestations of IgG4‐related urinary disease (IgG4‐RUD) and assess its treatment responses. Methods . We conducted a retrospective study enrolling 65 IgG4‐RUD patients from an IgG4‐related disease (IgG4‐RD) cohort of the Peking Union Medical College Hospital. Clinical, laboratory, radiological, pathological data were collected, and treatment response to immunosuppressants were analysed. Results . IgG4‐related interstitial nephritis (TIN, 32.3%), glomerular nephritis (GN, 7.7%), renal pelvis and ureter involvement (21.5%), abnormal radiology with quiescent clinical presentation (13.8%), and renal parenchymal lesion plus retroperitoneal fibrosis (RPF, 18.5%) were major lesion types of IgG4‐RUD. All patients had elevated serum IgG4, 76.9% had hyperglobulinemia, and 92.3% had elevated serum IgE at diagnosis. IgG4‐TIN patients presented with renal dysfunction, and 94.3% had low serum complement C3 and IgG4‐GN presented with nephrotic syndrome, while renal pelvis and ureter involvement had normal renal function and urinalysis. IgG4‐RPF with renal parenchymal involvement presented with acute renal dysfunction and required emergency medical intervention. Renal cortex low‐density areas, parenchyma or pelvis nodular mass, bilateral enlargement of the kidney, and renal pelvis and ureter mass/wall thickening were specific image patterns of IgG4‐RUD. Infiltration of plasma lymphocytes and storiform fibrosis were histopathological features of IgG4‐RUD. Patients showed satisfactory responses to immunosuppressive treatment, but complete recovery of renal function was difficult to achieve in IgG4‐TIN. Four patients (6.2%) experienced clinical relapses during the maintenance period. Conclusion . IgG4‐RUD had diverse lesion types and distinctive manifestations. Radiological examinations were helpful for diagnosis and treatment evaluation. Patients showed good initial response to immunosuppressive treatment but relapses could occur at the maintenance period.

16 August 2024 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
YNYuxue Nie
Yuxue Nie
NZNianyi Zhang
Nianyi Zhang
JLJingna Li
Jingna Li
DWDi Wu
Di Wu
YYYunjiao Yang
Yunjiao Yang
WZWen Zhang
Wen Zhang

29 March 2023 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
ZLZheng Liu
Zheng Liu
YNYuxue Nie
Yuxue Nie
YPYu Peng
Yu Peng
HLHui Lu
Hui Lu
PZPanpan Zhang
Panpan Zhang
XZXiaofeng Zeng
Xiaofeng Zeng

2 February 2023 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
PZPanpan Zhang
Panpan Zhang
HLHui Lu
Hui Lu
YPYu Peng
Yu Peng
RSRuijie Sun
Ruijie Sun
YNYuxue Nie
Yuxue Nie
WZWen Zhang
Wen Zhang
Full Papers; Authors: P. Zhang, H. Lu, Y. Peng, R. Sun, Y. Nie, J. Li, L. Peng, W. Zhang